Foley Partner David Rosen was quoted in an article that appeared in Genetic Engineering & Biotechnology News on October 12, 2011 titled “Extent of Feedback on RUO/IUO In Vitro Dx Draft Guidance Means Changes Not Expected Soon.” Rosen discusses draft guidance proposed by the FDA concerning the labeling of in vitro diagnostic (IVD) products marked “for research use only” (RUO) and “for investigational use only” (IUO). He states that some companies are concerned about what products they can sell as RUO/IUO tests and what they cannot under the FDA’s draft guidelines. Rosen recognizes the need for research, but notes that it is also important to ensure that people do not rely on tests that are not verified and validated.
People
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“